中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2008年
29期
2073-2076
,共4页
张勇%MA Yi%卢汉平%ZHOU Xiang-fu%谢瑶%GAO Jin-hui%梁昌盛
張勇%MA Yi%盧漢平%ZHOU Xiang-fu%謝瑤%GAO Jin-hui%樑昌盛
장용%MA Yi%로한평%ZHOU Xiang-fu%사요%GAO Jin-hui%량창성
前列腺肿瘤%寡核苷酸类%受体,雄激素
前列腺腫瘤%寡覈苷痠類%受體,雄激素
전렬선종류%과핵감산류%수체,웅격소
Prostatic neoplasms%Oligonucleotides%Receptors,androgen
目的 探讨三螺旋形成寡核苷酸(TFO)和反义寡核苷酸(ASO)对人前列腺癌裸鼠移植瘤雄激素受体(AR)表达和肿瘤细胞生长的抑制作用.方法 32只荷LNCaP-CA-2前列腺癌移植瘤裸鼠随机分成4组:TFO治疗组、ASO治疗组、序列对照寡核苷酸(SCO)非特异性对照组和阴性对照组.采用瘤内注射给药,寡核苷酸用量25 mg/kg,隔天给药1次,共14次.观察裸鼠体重和肿瘤体积变化.测量移植瘤重量计算抑瘤率,放射免疫分析法检测裸鼠血清前列腺特异抗原(PSA)水平,RT-PCR方法检测肿瘤组织AR Mrna表达,免疫组化和放射配基结合分析方法检测AR蛋白表达.结果 TFO和ASO均能有效抑制移植瘤生长,抑瘤率分别为67.55%和41.06%,与对照组相比差异有统计学意义(均P<0.01).TFO组的瘤重和肿瘤组织AR表达水平显著低于ASO组(均P<0.05),TFO组动物血清PSA水平[(6.6±1.0)ng/ml]也显著低于ASO组[(19.8±3.7)ng/ml,P<0.05].结论 TFO对前列腺癌裸鼠移植瘤AR表达和肿瘤生长的抑制作用强于ASO,具有较好的抗前列腺癌应用前景.
目的 探討三螺鏇形成寡覈苷痠(TFO)和反義寡覈苷痠(ASO)對人前列腺癌裸鼠移植瘤雄激素受體(AR)錶達和腫瘤細胞生長的抑製作用.方法 32隻荷LNCaP-CA-2前列腺癌移植瘤裸鼠隨機分成4組:TFO治療組、ASO治療組、序列對照寡覈苷痠(SCO)非特異性對照組和陰性對照組.採用瘤內註射給藥,寡覈苷痠用量25 mg/kg,隔天給藥1次,共14次.觀察裸鼠體重和腫瘤體積變化.測量移植瘤重量計算抑瘤率,放射免疫分析法檢測裸鼠血清前列腺特異抗原(PSA)水平,RT-PCR方法檢測腫瘤組織AR Mrna錶達,免疫組化和放射配基結閤分析方法檢測AR蛋白錶達.結果 TFO和ASO均能有效抑製移植瘤生長,抑瘤率分彆為67.55%和41.06%,與對照組相比差異有統計學意義(均P<0.01).TFO組的瘤重和腫瘤組織AR錶達水平顯著低于ASO組(均P<0.05),TFO組動物血清PSA水平[(6.6±1.0)ng/ml]也顯著低于ASO組[(19.8±3.7)ng/ml,P<0.05].結論 TFO對前列腺癌裸鼠移植瘤AR錶達和腫瘤生長的抑製作用彊于ASO,具有較好的抗前列腺癌應用前景.
목적 탐토삼라선형성과핵감산(TFO)화반의과핵감산(ASO)대인전렬선암라서이식류웅격소수체(AR)표체화종류세포생장적억제작용.방법 32지하LNCaP-CA-2전렬선암이식류라서수궤분성4조:TFO치료조、ASO치료조、서렬대조과핵감산(SCO)비특이성대조조화음성대조조.채용류내주사급약,과핵감산용량25 mg/kg,격천급약1차,공14차.관찰라서체중화종류체적변화.측량이식류중량계산억류솔,방사면역분석법검측라서혈청전렬선특이항원(PSA)수평,RT-PCR방법검측종류조직AR Mrna표체,면역조화화방사배기결합분석방법검측AR단백표체.결과 TFO화ASO균능유효억제이식류생장,억류솔분별위67.55%화41.06%,여대조조상비차이유통계학의의(균P<0.01).TFO조적류중화종류조직AR표체수평현저저우ASO조(균P<0.05),TFO조동물혈청PSA수평[(6.6±1.0)ng/ml]야현저저우ASO조[(19.8±3.7)ng/ml,P<0.05].결론 TFO대전렬선암라서이식류AR표체화종류생장적억제작용강우ASO,구유교호적항전렬선암응용전경.
Objective To investigate the effects of triple-helix forming oligonucleotide (TFO) and antisense oligonucleotide (ASO) on androgen receptor (AR) expression and tumor growth of human prostate cancer xenografts in nude mice.Methods Thirty-two nude mice were inoculated with human prostate cancer cells of the line LNCaP-C4-2 were randomized into 4 equal groups:TFO treatment group,undergoing intra-tumor injection of TFO at the dose of 25 mg · kg-1 · (2d)-1 for 14 times,ASO treatment group, undergoing intra-tumor injection of ASO at the same dose for 14 times,SCO group,undergoing intra-rumor injection of sequence control oligonucleotide (SCO) at the same dose for 14 times,and control group.The body weight and xenograft tumor volume of the nude mice were monitored during the therapy.28 days later venous blood samples were collected to measure the level of prostate specific antigen (PSA) by radioimmunoassay and then the mice were killed with their tumors taken out to measure the weight,and RTPCR,immunohistochemistry,and radioligand binding assay were used to detect the AR gene mRNA and protein expression in the tumor tissues.Results By the end of experiment the volumes and weights of tumor of the ASO and ASO groups were all significantly lower than those of the control group ( all P < 0.01 ) with the inhibition rates of 67.55% and 41.06% respectively,and the volumes and weights of tumor of the TFO group were all significantly lower than those of the ASO group ( all P < 0.05 ).The tumor weight and AR expression levels of TFO group were significantly lower than those of ASO group ( P < 0.05 ).The serum PSA level of TFO group was (6.6 ± 1.0) ng/ml,significantly lower than that of the ASO group [ ( 19.8 ± 3.7) ng/ml,P < 0.05 ].The mRNA and protein expression levels of AR of the TFO group were significantly lower than those of the other groups ( all P < 0.05).There were no significant differences in all the above mentioned markers between the SCO and control groups ( all P > 0.05 ) .Conclusion TFO shows significantly higher inhibitory effect on AR expression and tumor growth of human prostate cancer xenograft than ASO,and is a promising agent for prostate cancer gene therapy.